Search results

Title: Comparative Industrial Operations Analysis (semester?), IPRO 312: Comparative Industiral Operations IPRO 312 Final Report Sp07
Creator: Logisz, Robert, Parry, Edward, Walters, Dominic, Simmons, Priscilla, Bilitz, Elizabeth, Shun, Hosung, Hagan, Michael, Kim, Hong-kwon, Larson, Scott, Olsen, Keith, Schejbal, Jeffrey, Ziskovsky, Anthony
Date: 2007-05, 2007-05
Description: IPRO 312 for Spring 2007 was initially intended to research rapid response manufacturing of casters for Colson Associates; however, as...
Show moreIPRO 312 for Spring 2007 was initially intended to research rapid response manufacturing of casters for Colson Associates; however, as objectives of the company shifted course, IPRO 312 was left without a target of research. A new idea of pharmaceuticals arose as a topic of study. The teammates were determined to hunt for information pertaining to problems in the pharmaceutical field, but this determination was cut short by the realization that it is a very secure, secretive, and private business. The teammates of this IPRO were not discouraged by this obstacle and kept pressing for information. The advisor, Prof. Maurer, brought in speakers from the field and helped the class change its direction into what it is today: Comparative Industrial Operations Analysis.
Deliverables for IPRO 312: Comparative Industrial Operations Analysis for the Spring 2007 semester
Show less

Title: ACCELPharma (semester?), IPRO 353: ACCELPharma IPRO 353 IPRO Day Presentation F06
Creator: Josefsson, Gustaf, Ames, Kerry, Calizo, Milagros, Schiller, Brian, Groth, Kristel, Ervin, Natalia, Holmes, Matt, Lee, Hyun, Lim, Eung, Ravi, Iyengar
Date: 2006-12, 2006-12
Description: AccelPharma intends to enable pharmaceutical and biotech companies to reintroduce withdrawn drugs to the market place through the development,...
Show moreAccelPharma intends to enable pharmaceutical and biotech companies to reintroduce withdrawn drugs to the market place through the development, validation, and deployment of personalized medicine models. It differentiates itself by being one of the only companies to correlate side effects of drugs to certain genetic mutations for a broad range of effects. AccelPharma expects to break even and begin to achieve positive revenues after only the second sale.
Deliverables for IPRO 353: ACCELPharma for the Fall 2006 semester.
Show less

Title: Comparative Industrial Operations Analysis (semester?), IPRO 312
Creator: Logisz, Robert, Parry, Edward, Walters, Dominic, Simmons, Priscilla, Bilitz, Elizabeth, Shun, Hosung, Hagan, Michael, Kim, Hong-kwon, Larson, Scott, Olsen, Keith, Schejbal, Jeffrey, Ziskovsky, Anthony
Date: 2007-05, 2007-05
Description: IPRO 312 for Spring 2007 was initially intended to research rapid response manufacturing of casters for Colson Associates; however, as...
Show moreIPRO 312 for Spring 2007 was initially intended to research rapid response manufacturing of casters for Colson Associates; however, as objectives of the company shifted course, IPRO 312 was left without a target of research. A new idea of pharmaceuticals arose as a topic of study. The teammates were determined to hunt for information pertaining to problems in the pharmaceutical field, but this determination was cut short by the realization that it is a very secure, secretive, and private business. The teammates of this IPRO were not discouraged by this obstacle and kept pressing for information. The advisor, Prof. Maurer, brought in speakers from the field and helped the class change its direction into what it is today: Comparative Industrial Operations Analysis.
Deliverables for IPRO 312: Comparative Industrial Operations Analysis for the Spring 2007 semester
Show less

Title: Comparative Industrial Operations Analysis (semester?), IPRO 312: Comparative Industiral Operations IPRO 312 Abstract Sp07
Creator: Logisz, Robert, Parry, Edward, Walters, Dominic, Simmons, Priscilla, Bilitz, Elizabeth, Shun, Hosung, Hagan, Michael, Kim, Hong-kwon, Larson, Scott, Olsen, Keith, Schejbal, Jeffrey, Ziskovsky, Anthony
Date: 2007-05, 2007-05
Description: IPRO 312 for Spring 2007 was initially intended to research rapid response manufacturing of casters for Colson Associates; however, as...
Show moreIPRO 312 for Spring 2007 was initially intended to research rapid response manufacturing of casters for Colson Associates; however, as objectives of the company shifted course, IPRO 312 was left without a target of research. A new idea of pharmaceuticals arose as a topic of study. The teammates were determined to hunt for information pertaining to problems in the pharmaceutical field, but this determination was cut short by the realization that it is a very secure, secretive, and private business. The teammates of this IPRO were not discouraged by this obstacle and kept pressing for information. The advisor, Prof. Maurer, brought in speakers from the field and helped the class change its direction into what it is today: Comparative Industrial Operations Analysis.
Deliverables for IPRO 312: Comparative Industrial Operations Analysis for the Spring 2007 semester
Show less

Title: ACCELPharma (semester?), IPRO 353: ACCELPharma IPRO 353 Abstract F06
Creator: Josefsson, Gustaf, Ames, Kerry, Calizo, Milagros, Schiller, Brian, Groth, Kristel, Ervin, Natalia, Holmes, Matt, Lee, Hyun, Lim, Eung, Ravi, Iyengar
Date: 2006-12, 2006-12
Description: AccelPharma intends to enable pharmaceutical and biotech companies to reintroduce withdrawn drugs to the market place through the development,...
Show moreAccelPharma intends to enable pharmaceutical and biotech companies to reintroduce withdrawn drugs to the market place through the development, validation, and deployment of personalized medicine models. It differentiates itself by being one of the only companies to correlate side effects of drugs to certain genetic mutations for a broad range of effects. AccelPharma expects to break even and begin to achieve positive revenues after only the second sale.
Deliverables for IPRO 353: ACCELPharma for the Fall 2006 semester.
Show less

Title: Comparative Industrial Operations Analysis (semester?), IPRO 312: Comparative Industiral Operations IPRO 312 Project Plan Sp07
Creator: Logisz, Robert, Parry, Edward, Walters, Dominic, Simmons, Priscilla, Bilitz, Elizabeth, Shun, Hosung, Hagan, Michael, Kim, Hong-kwon, Larson, Scott, Olsen, Keith, Schejbal, Jeffrey, Ziskovsky, Anthony
Date: 2007-05, 2007-05
Description: IPRO 312 for Spring 2007 was initially intended to research rapid response manufacturing of casters for Colson Associates; however, as...
Show moreIPRO 312 for Spring 2007 was initially intended to research rapid response manufacturing of casters for Colson Associates; however, as objectives of the company shifted course, IPRO 312 was left without a target of research. A new idea of pharmaceuticals arose as a topic of study. The teammates were determined to hunt for information pertaining to problems in the pharmaceutical field, but this determination was cut short by the realization that it is a very secure, secretive, and private business. The teammates of this IPRO were not discouraged by this obstacle and kept pressing for information. The advisor, Prof. Maurer, brought in speakers from the field and helped the class change its direction into what it is today: Comparative Industrial Operations Analysis.
Deliverables for IPRO 312: Comparative Industrial Operations Analysis for the Spring 2007 semester
Show less

Title: ACCELPharma (semester?), IPRO 353: ACCELPharma IPRO 353 Poster F06
Creator: Josefsson, Gustaf, Ames, Kerry, Calizo, Milagros, Schiller, Brian, Groth, Kristel, Ervin, Natalia, Holmes, Matt, Lee, Hyun, Lim, Eung, Ravi, Iyengar
Date: 2006-12, 2006-12
Description: AccelPharma intends to enable pharmaceutical and biotech companies to reintroduce withdrawn drugs to the market place through the development,...
Show moreAccelPharma intends to enable pharmaceutical and biotech companies to reintroduce withdrawn drugs to the market place through the development, validation, and deployment of personalized medicine models. It differentiates itself by being one of the only companies to correlate side effects of drugs to certain genetic mutations for a broad range of effects. AccelPharma expects to break even and begin to achieve positive revenues after only the second sale.
Deliverables for IPRO 353: ACCELPharma for the Fall 2006 semester.
Show less

Title: Comparative Industrial Operations Analysis (semester?), IPRO 312: Comparative Industiral Operations IPRO 312 IPRO Day Presentation Sp07
Creator: Logisz, Robert, Parry, Edward, Walters, Dominic, Simmons, Priscilla, Bilitz, Elizabeth, Shun, Hosung, Hagan, Michael, Kim, Hong-kwon, Larson, Scott, Olsen, Keith, Schejbal, Jeffrey, Ziskovsky, Anthony
Date: 2007-05, 2007-05
Description: IPRO 312 for Spring 2007 was initially intended to research rapid response manufacturing of casters for Colson Associates; however, as...
Show moreIPRO 312 for Spring 2007 was initially intended to research rapid response manufacturing of casters for Colson Associates; however, as objectives of the company shifted course, IPRO 312 was left without a target of research. A new idea of pharmaceuticals arose as a topic of study. The teammates were determined to hunt for information pertaining to problems in the pharmaceutical field, but this determination was cut short by the realization that it is a very secure, secretive, and private business. The teammates of this IPRO were not discouraged by this obstacle and kept pressing for information. The advisor, Prof. Maurer, brought in speakers from the field and helped the class change its direction into what it is today: Comparative Industrial Operations Analysis.
Deliverables for IPRO 312: Comparative Industrial Operations Analysis for the Spring 2007 semester
Show less

Title: ACCELPharma (semester?), IPRO 353: ACCELPharma IPRO 353 Midterm Presentation F06
Creator: Josefsson, Gustaf, Ames, Kerry, Calizo, Milagros, Schiller, Brian, Groth, Kristel, Ervin, Natalia, Holmes, Matt, Lee, Hyun, Lim, Eung, Ravi, Iyengar
Date: 2006-12, 2006-12
Description: AccelPharma intends to enable pharmaceutical and biotech companies to reintroduce withdrawn drugs to the market place through the development,...
Show moreAccelPharma intends to enable pharmaceutical and biotech companies to reintroduce withdrawn drugs to the market place through the development, validation, and deployment of personalized medicine models. It differentiates itself by being one of the only companies to correlate side effects of drugs to certain genetic mutations for a broad range of effects. AccelPharma expects to break even and begin to achieve positive revenues after only the second sale.
Deliverables for IPRO 353: ACCELPharma for the Fall 2006 semester.
Show less

Title: ACCELPharma (semester?), IPRO 353
Creator: Josefsson, Gustaf, Ames, Kerry, Calizo, Milagros, Schiller, Brian, Groth, Kristel, Ervin, Natalia, Holmes, Matt, Lee, Hyun, Lim, Eung, Ravi, Iyengar
Date: 2006-12, 2006-12
Description: AccelPharma intends to enable pharmaceutical and biotech companies to reintroduce withdrawn drugs to the market place through the development,...
Show moreAccelPharma intends to enable pharmaceutical and biotech companies to reintroduce withdrawn drugs to the market place through the development, validation, and deployment of personalized medicine models. It differentiates itself by being one of the only companies to correlate side effects of drugs to certain genetic mutations for a broad range of effects. AccelPharma expects to break even and begin to achieve positive revenues after only the second sale.
Deliverables for IPRO 353: ACCELPharma for the Fall 2006 semester.
Show less

Title: ACCELPharma (semester?), IPRO 353: ACCELPharma IPRO 353 Final Report F06
Creator: Josefsson, Gustaf, Ames, Kerry, Calizo, Milagros, Schiller, Brian, Groth, Kristel, Ervin, Natalia, Holmes, Matt, Lee, Hyun, Lim, Eung, Ravi, Iyengar
Date: 2006-12, 2006-12
Description: AccelPharma intends to enable pharmaceutical and biotech companies to reintroduce withdrawn drugs to the market place through the development,...
Show moreAccelPharma intends to enable pharmaceutical and biotech companies to reintroduce withdrawn drugs to the market place through the development, validation, and deployment of personalized medicine models. It differentiates itself by being one of the only companies to correlate side effects of drugs to certain genetic mutations for a broad range of effects. AccelPharma expects to break even and begin to achieve positive revenues after only the second sale.
Deliverables for IPRO 353: ACCELPharma for the Fall 2006 semester.
Show less

repository.iit

Search the repository

Enabled Filters

Refine Results

Type

Date

Department

Subject

Creator

Rights